Lemonaid Health
Online doctor visits and prescriptions
Telehealth platform offering GLP-1 medications through subscription-based weight loss program with transparent pricing. Sold to Bambu Ventures in September 2025 after 23andMe bankruptcy.
Medications Available
Pros
- Nationwide availability (all 50 states + DC)
- Transparent pricing (doesn't change with dose)
- No long-term commitment
- Video or phone consultations
- LillyDirect partnership for Zepbound
- Promotional pricing available ($129/mo compounded semaglutide)
Cons
- New ownership (Bambu Ventures) - monitor stability
- No nutrition coaching or lifestyle support
- Membership fee ($49/mo) plus medication costs
- Focuses primarily on medication management
- Originally acquired for $400M, sold for $10M - significant devaluation
Compare Lemonaid Health With
See how Lemonaid Health stacks up against other providers
About Lemonaid Health
Lemonaid Health is a leading telemedicine provider, a subsidiary of 23andMe Holding Co., founded in 2013 in San Francisco, CA. They offer GLP-1 medications through a subscription-based weight loss program with transparent pricing that doesn’t change based on dosage.
How It Works
- Join Membership - $49/month subscription
- Consultation - Video or phone visit with clinician
- Get Prescription - Transparent, dose-independent pricing
- Ongoing Care - Annual lab order included as needed
Pricing (March 2026)
| Plan | Price | Notes |
|---|---|---|
| Weight Loss Membership | $49/mo | Consultations, prescription, ongoing care, annual labs |
| Compounded Semaglutide (promo) | $129/mo | Limited time promotional rate |
| Compounded Semaglutide (3-month plan) | $249/mo | All doses - price doesn’t change |
| Compounded Semaglutide (monthly) | $299/mo | Month-to-month, all doses |
| Compounded Semaglutide Microdose | $199/mo | Lower dose option |
| Ozempic (brand) | $1,199/mo | FDA-approved |
| Wegovy (brand) | $1,599/mo | FDA-approved |
| Zepbound Vials (via LillyDirect) | $299-$449/mo | 2.5mg-15mg doses |
No long-term commitment required.
Corporate Changes (Important)
September 2025: Lemonaid Health was sold to Bambu Ventures (in partnership with Innova Capital Partners) for $10 million following 23andMe’s bankruptcy filing in March 2025. 23andMe originally acquired Lemonaid for $400 million in 2021.
New Leadership: Bambu’s Kyle Pretsch and Dylan Runne are leading operations, with plans to expand on-demand telehealth and online pharmacy services.
Who Is This Best For?
- Patients in any US state (nationwide + DC coverage)
- Those wanting predictable, transparent pricing
- People interested in LillyDirect Zepbound access
- Patients seeking no long-term commitment
The Bottom Line
Lemonaid Health offers straightforward GLP-1 access with transparent pricing and nationwide availability. Under new Bambu Ventures ownership, the platform continues to operate but the significant devaluation ($400M to $10M) warrants monitoring for service stability.
Last updated: March 2026
Last verified: April 2026
Ready to try Lemonaid Health?
Compare with other providers or visit their website to get started.